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Abstract
Background Especially in elderly with polypharmacy, medication can do harm. Clinical pharmacists integrated in primary 
care teams might improve quality of pharmaceutical care. Objective To assess the effect of non-dispensing clinical pharma-
cists integrated in primary care teams on general practitioners’ prescribing quality. Setting This study was conducted in 25 
primary care practices in the Netherlands. Methods Non-randomised, controlled, multi-centre, complex intervention study 
with pre-post comparison. First, we identified potential prescribing quality indicators from the literature and assessed their 
feasibility, validity, acceptability, reliability and sensitivity to change. Also, an expert panel assessed the indicators’ health 
impact. Next, using the final set of indicators, we measured the quality of prescribing in practices where non-dispensing phar-
macists were integrated in the team (intervention group) compared to usual care (two control groups). Data were extracted 
anonymously from the healthcare records. Comparisons were made using mixed models correcting for potential confound-
ers. Main outcome measure Quality of prescribing, measured with prescribing quality indicators. Results Of 388 eligible 
indicators reported in the literature we selected 8. In addition, two more indicators relevant for Dutch general practice were 
formulated by an expert panel. Scores on all 10 indicators improved in the intervention group after introduction of the non-
dispensing pharmacist. However, when compared to control groups, prescribing quality improved solely on the indicator 
measuring monitoring of the renal function in patients using antihypertensive medication: relative risk of a monitored renal 
function in the intervention group compared to usual care: 1.03 (95% CI 1.01–1.05, p-value 0.010) and compared to usual 
care plus: 1.04 (1.01–1.06, p-value 0.004). Conclusion This study did not demonstrate a consistent effect of the introduction 
of non-dispensing clinical pharmacists in the primary care team on the quality of physician’s prescribing.
This study is part of the POINT-study, which was registered at The Netherlands National Trial Register with trial registra-
tion number NTR‐4389.
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Abbreviations
GP  General practitioner
NDP  Non-dispensing pharmacist
POINT  Pharmacotherapy optimisation through integrat-
ing a non-dispensing pharmacist in primary care 
teams
Impacts on Practice
• Prescribing indicators might not capture the full effect of 
non-dispensing pharmacists integrated in primary care 
teams, when interventions are not specifically targeted 
upon these indicators.
• A non-dispensing pharmacist integrated in the primary 
care team improves the monitoring of renal function in 
patients using diuretics, compared to usual care.
• Future studies on complex, generic interventions should 
use a mixed methods design to evaluate the effects on 
quality of care.
Background
To prevent medication-related harm in the expanding group 
of elderly with polypharmacy [1, 2], various innovations in 
the organisation of pharmaceutical care are currently imple-
mented. Integration of clinical pharmacists in primary care 
teams potentially improves the quality and safety of pharma-
cotherapy and is currently being evaluated in various formats 
in Canada, Australia, the United Kingdom and Ireland [3–6]. 
Also in the Netherlands a non-dispensing clinical pharma-
cist (NDP), providing patient-centred pharmaceutical care in 
close collaboration with the general practitioner (GP), was 
recently introduced [7].
Clinical pharmacy services provided by such pharma-
cists in primary care can be either disease-specific, tailored 
to a patient population with a specific medical condition; 
or patient-centred, when provided to a more heterogene-
ous patient population, such as patients with polypharmacy, 
patients prescribed at least one medication or patients at risk 
of medication problems [8].
So far, largest impact of this new care model was found 
when pharmacists were fully integrated into primary care 
teams, providing multifaceted interventions and follow up to 
patients, and with the possibility of face-to-face communica-
tion between pharmacist and GP [9, 10]. Effects are mainly 
found on reducing drug therapy problems and improving 
proxy outcomes (such as blood pressure control or decreas-
ing HbA1c levels). Yet, effects on prescription quality indi-
cators, commonly used for quality monitoring on practice 
level by regulators and insurers, is scarce.
Aim of the study
Despite the promising results, integration of pharmacists 
in primary care teams has not been adopted widely yet. In 
this study, we evaluated the effect of patient-centred care 
delivered by NDPs integrated in primary care teams on 
medication safety on a practice level. Hereto, we compared 
NDP-led care with usual care on prescription outcomes, as 
indicator of quality of pharmaceutical patient care [11].
Methods
This study was part of the Pharmacotherapy Optimisation 
through Integration of a Non-dispensing pharmacist in pri-
mary care Teams (POINT) study [7]: a non-randomised, 
controlled intervention study, comparing NDP-led care 
(intervention group) with two current models of pharma-
ceutical care (control groups).
The integration of an NDP in primary care teams should 
be considered as a complex intervention, as it comprises of 
different interacting components, targets multiple levels of 
organisation, has variable outcomes and needs to be tailored 
to the context in which it is implemented [12, 13]. Hence, its 
evaluation should be multidimensional, including a theoreti-
cal framework underlying the expected intervention effect, 
and assessment of feasibility, effectiveness and related pro-
cess changes. The theoretical framework as well as results 
on feasibility and effectiveness have been described else-
where [14–16]; in the present study we focus on the process 
changes as measured with indicators that can be derived 
from computerised healthcare records.
Ethics approval
The POINT protocol was reviewed by the Medical Ethical 
Committee of the University Medical Center Utrecht and 
was deemed not eligible for full assessment (METC protocol 
number 13-432C). Patient data were extracted anonymously, 
according to data protection regulations.
Intervention and control groups
For the POINT study, ten (PharmD) pharmacists were 
trained as NDPs in a 15-months training program [17]. 
These NDPs were attached to general practices, collabo-
rating closely with the GPs while being fully integrated 
in the team. Their key activities were both on a patient 
level, providing clinical medication reviews and patient 
consultations for medication problems, as well as on a 
practice level, educating staff and implementing quality 
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improvement projects. For these quality improvement 
projects, the NDPs were allowed to select different topics, 
tailored to the needs of the practice. The NDPs mainly 
focussed on care for elderly with polypharmacy, but pro-
vided pharmaceutical care for younger patients or those 
with less medications as well (especially in improvement 
projects). Their role was allowed to evolve during the 
trial and, if needed, to be adjusted to the needs of daily 
practice. Most NDPs were relatively at the beginning of 
their career, with working experience varying from less 
than 1 year (n = 3), 1–3 years (n = 5) and between 5 and 
10 years (n = 2); mainly in community pharmacies (n = 9). 
The NDPs were blinded for outcome measures (except for 
the primary outcome: medication-related hospital admis-
sions) during the study period.
Intervention group practices were included only when 
they were explicitly willing to host an NDP, as willing-
ness of all participating parties to improve pharmaceutical 
patient care has been recognised as a key condition for 
successfully implementing an NDP in primary care [3].
Two control groups consisted of the “usual care 
group”, in which pharmaceutical care was provided by 
local community pharmacists, and the “usual care plus 
group”, in which community pharmacists had an addi-
tional training [18, 19] in performing clinical medica-
tion reviews. Control group practices were matched to the 
practices in the intervention group as much as possible, 
with regard to practice size, degree of urbanisation, socio-
economic status and patients’ age distribution. Full details 
of the design of the POINT-study have been described 
elsewhere [7].
Setting and patients
This study was performed in all 25 general practices that 
participated in the POINT-study. Patients registered in 
one of these practices, aged 50 years or older and using 
at least one type of chronic medication (defined as having 
3 or more prescriptions per year of the same ATC-3-level 
medication) were included.
Study period
We did a pre-post comparison, comparing the prescribing 
quality during 2013 (pre period) with the prescribing qual-
ity in the intervention year, starting June 1st 2014 until May 
31st 2015 (post period). The NDPs worked full time in the 
practices during the intervention year.
Outcome: quality of prescribing
To evaluate the GPs’ prescribing quality, we used process 
indicators, as these have been reported most sensitive to dif-
ferences in quality of care: they are easier to interpret than 
outcome indicators, and are usually more sensitive to small 
differences [20].
Selection of indicators
We collected indicators from literature and policy docu-
ments. Indicators were assessed step-wise, including assess-
ment of feasibility, validity, acceptability, reliability and 
sensitivity to change (Box 1) [11] and health impact. Addi-
tional indicators were formulated if needed. For details of 
the selection procedure, see Online Supplement 1.
Data collection
We used anonymised healthcare data routinely extracted 
from the GPs’ electronic medical records. These data com-
prised of basic patient characteristics, such as sex and age, 
and contained all prescribed medications, registered comor-
bidities and lab tests performed during the study periods. We 
also collected data on the five months prior to both periods, 
as for some indicators a timeframe of more than one year 
was required.
Sample size calculation
No separate sample size calculation was performed. Data 
were considered a secondary outcome measurement of the 
POINT-study, for which a sample size calculation on the 
primary outcome (medication-related hospitalisations) was 
Box 1  Criteria that quality indicators were assessed on [11]
Criteria Description
Feasibility Whether the data needed to calculate the indicator were available in our database
Validity Whether the content of the indicator was clinically relevant, based upon current guidelines and scientific publications
Acceptability Whether assessment of the indicator was acceptable for both the patient and the healthcare provider
Reliability Whether other factors than the prescribing behaviour of the GP could influence the outcome of the indicator, and 
whether these factors would differ between the study groups
Sensitivity to change Whether the indicator would detect changes and differences in quality of care
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performed [7]. Outcomes on the primary outcome have been 
described elsewhere [16].
Analysis
Scores on indicators are reported as percentages. Differences 
in scores over time were reported per study group, but as 
practices were not randomised, those differences should not 
be formally compared. Hence, performance per indicator 
was compared between study groups using mixed models. 
For a detailed description of the mixed models, see Online 
Supplement 2. The Consort-checklist for non-randomised 




The PubMed-search yielded 42 articles, of which 16 were 
considered relevant. From these, 318 indicators were 
included. From professional and policy literature we col-
lected an additional 141 indicators. After removing dupli-
cates, 388 indicators remained for assessment, resulting in 
8 eligible indicators (see Fig. 1). Of those, two concerned 
long-term medication use. Because of the nature of our 
intervention, we needed to alter the definition of ‘long-term’ 
used in these two indicators in order to enable the indicators 
to adequately capture change in prescribing quality.
Two additional indicators were formulated by the expert 
panel. The ten final indicators are summed in Box 2.
Participating practices
One NDP stopped during the study period, so we evaluated 
prescribing quality of 9 practices in the intervention group. 
In the control groups, for the usual care group 10 practices 
and for the usual care plus group 6 practices were included. 
Intervention and control practices were comparable with 
respect to practice characteristics and patient demograph-
ics, except for practice size (see Table 1).
Fidelity of the intervention
All NDPs implemented quality improvement projects in 
their practices, but content and scheduling of these pro-
jects varied: some projects were implemented right after 
the NDPs started working in the practice, but others were 
(partly) implemented only two months before the interven-
tion period ended. This may have limited their effect. The 
number of projects per practice ranged from 1 to 14 (median 
10). Box 3 gives an overview of the covered topics. Six top-
ics matched with clinical themes of the final indicator set.
Quality of prescribing
In the intervention group, all indicators of desirable pre-
scribing improved, while those measuring undesirable pre-
scribing decreased (Table 2). In the control groups compa-
rable trends were seen, but not for all indicators (for details, 
see Online Supplement 4).
After correction for potential confounders and taking the 
baseline differences into account in mixed models, 4 out 
of 10 indicators differed between intervention and control 
group (Table 3, and described in detail in Online Supple-
ment 4).
Discussion
We assessed the effect of NDPs integrated in primary care 
teams on the quality of GP prescribing, using 10 selected 
indicators of prescribing quality. Although the scores of all 
quality indicators improved in the intervention group, and 
not in the control groups, we could not demonstrate a con-
sistent favourable effect of NDP introduction on prescribing 
quality after correction for baseline differences and potential 
confounders.
Comparison with existing literature
To our knowledge, only few studies have used process indi-
cators to assess effects of integrating an NDP in primary 
care teams. In Canada, the effect of integrating a team of 
a pharmacist and nurse practitioners in primary care was 
measured using indicators on quality of care for chronic dis-
ease management [26]. Most of these indicators concerned 
prescribing (for example: recommended aspirin in patients 
with coronary artery disease), but some regarded physical 
examinations (for example: feet examination in patients with 
diabetes). Comparable to our study, all indicators improved 
over time after introduction of the intervention, when exam-
ined within the intervention group alone (except for two 
indicators in which performance was considered relatively 
high already at baseline). In contrast to our study, the perfor-
mance of the intervention group was subsequently compared 
to a control group using a composite indicator. This showed 
a result in favour of the intervention group. We did not use 
a composite indicator, as a composite is very dependent on 
the way it is constructed: differently constructed composite 
scores can even result into different conclusions being drawn 
about quality, especially when they include a wide range of 
medical conditions, different numbers of indicators triggered 
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by a patient and when they include both frequently and more 
rarely triggered indicators [27].
In a United Kingdom-based study, the effect of a phar-
macist-led information technology intervention in primary 
care on prescribing quality was assessed [28]. In com-
parison to a control group receiving only simple feedback, 
significant differences in favour of the intervention group 
for seven of the 12 measured indicators were found. This 
result may be explained by the fact that the pharmacist-
led information technology intervention was specifically 
targeted on the measured indicators, while in our study 
NDP-led care was mainly broadly implemented: focus-
sing on specific interventions can increase the potential to 
detect change. Although the quality improvement projects 
Fig. 1  Flowchart of assessment of indicators
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implemented by the NDPs were targeted at specific 
patients groups, the variation in projects among practices 
was still substantial (see Table 2). Although this variation 
was explicitly allowed, the resulting heterogeneity and 
dilution may explain the absence of a consistent effect on 
the prescribing quality indicators.
Interpretation of results
We did not find a consistent effect of the integration of NDPs 
in primary care teams on prescription indicators. Although 
prescription indicators are considered a suitable measure-
ment for medication safety effects, they may be too specific 
to assess the true effect of a heterogeneous intervention such 
as patient-centred NDP-led care.
Still, we found some specific effects that resulted from 
the NDP intervention: in practices with an integrated NDP, 
the renal function was monitored more frequently in patients 
using antihypertensives, compared to in usual care practices. 
We think this is a result from the clinical medication reviews 
performed by NDPs, as renal function monitoring was not 
frequently part of the quality improvement projects. This 
finding adds to the evidence that the quality of clinical phar-
macy services improves when the pharmacist is embedded in 
clinical practice: NDPs are fully integrated in primary care 
teams, whilst community pharmacists operate separately 
from general practice teams. This is also illustrated by a 
previous finding that recommendations given by NDPs were 
more frequently followed by GPs, compared to recommen-
dations by community pharmacists [29].
Box 2  Final set of prescribing quality indicators, per category
NSAID Non Steroid Anti-Inflammatory Drug, PPI Proton Pump Inhibitor, LDL Low Density Lipoprotein, mg milligrams, ACEi Angiotensin-
Converting Enzyme inhibitor, ATII-RA Angiotensin II type 2 receptor antagonist, CVD Cardiovascular Disease, COX-2 Cyclo-oxygenase-2, RAS 
Renin-Angiotensin System
Although categories describe potential prescription errors, indicators are formulated as both undesirable care (and hence indeed potential errone-
ous prescribing) and desirable care (and hence potential correct prescribing):
a This category contains indicators representing desirable care, hence a higher score is generally preferable
b This category contains indicators representing undesirable care, hence a lower score is generally preferable
All indicators were assessed for the pre and the post period, selecting element of the indicator from that specific study period
‘Using’ was defined as having one or more prescriptions of the medication named
‘Using on a chronic basis’ was defined as having three or more prescriptions of the medication named
Indicators No. 3. and 5. were formulated by the expert panel, and are hence not validated. Indicators No. 7. and 8. contain altered durations of 
medication use compared to the original indicators, in order to make them susceptible to eventual change
Underprescribinga
 1. PPIs and NSAIDs Patients aged 70 years or older using non-selective NSAIDs (denominator), using a PPI (numerator)
 2. LDL in CVD history Patients aged younger than 80 years, with a history of cardiovascular disease and at least one measure-
ment of LDL (denominator), having their last LDL-measurement being 2.5 mmol/L or lower with or 
without statin treatment (numerator)
Dosing errorb
 3. HCT dose Patients aged 80 years or older using hydrochlorothiazide (denominator), of which the dose is 25 mg/day 
or higher (numerator)
 4. Digoxin dose Patients aged 70 years or older and using digoxin (denominator), of which the dose is over 0.125 mg/day 
(if aged 71–85 years) or over 0.0625 mg/day (if aged 86 +) (numerator)
Therapeutic duplicationb
 5. ACEi and ATII-RA Patients using one or more antihypertensive medications on a chronic basis (denominator), who use both 
an ACE-inhibitor and an AT-II-antagonist chronically (numerator)
Contra-indicatedb
 6. NSAIDs in CVD history Patients with a history of cardiovascular disease (denominator), using COX-2 selective NSAIDs 
(numerator)
Medication not effectiveb
 7. Benzodiazepines Patients aged 65 years or older (denominator), using benzodiazepines for > 300 days per year (numera-
tor)
Overprescribingb
 8. Antidepressants All patients (denominator), using antidepressants for > 450 days during period of 17 months (numerator)
Inadequate monitoringa
 9. Diuretics and renal function Patients using diuretics and/or RAS-inhibitors (denominator), with known renal function and known 
potassium levels (numerator)
 10. Thyroid medication and function Patients using thyroid medication (denominator), with known thyroid function (numerator)
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In contrast, we found that in the intervention group 
patients with a history of cardiovascular disease were pre-
scribed NSAIDs more often as compared to control groups. 
As almost all NDPs had the use of NSAIDs in CVD patients 
incorporated in their quality improvement projects (n = 8), 
this does appear as an unexpected negative outcome. How-
ever, we suggest this may be related to the composition of 
the indicator: whilst quality improvement projects were 
implemented during the intervention year, the indicator 
measured NSAID-use with a single prescription at any time 
in the intervention year. Hence, it could be that the indicator 
underestimated the intervention effect, as changes following 
interventions in patients after a first prescription were not 
captured by the indicator anymore.
Strengths and limitations
This study has several strengths. We thoroughly assessed a 
broad selection of indicators, in order to achieve a reliable 
set to measure the effect of a non-dispensing pharmacist in 
primary care teams on GPs’ prescribing. Furthermore, the 
intervention was multifaceted and tailored to the practice 
and patients’ needs, in a real-world clinical environment. 
Including patients on a practice level might increase gener-
alisability of results.
Some limitations need to be taken into account as well. 
First of all, the fact that we—deliberately—chose not to ran-
domise participating practices, may have biased the compar-
ison between the study groups. We corrected for this using 
mixed models, adjusting for potential relevant baseline char-
acteristics, however bias can’t be fully ruled out.
Second, two limitations concern the use of indicators to 
measure quality. These limitations are in fact characteris-
tics of indicators that are important to be aware of when 
interpreting data on indicators, and hence are more a gen-
eral constraint of using indicators as outcome measurement 
rather than a specific limitation of this study. First, an indi-
cator can measure only a part of the care provided; it will 
never reflect the total quality of care. By selecting a set of 
indicators, we tried to gain a wider insight into the quality 
of prescribing during the provision of NDP-led pharmaceu-
tical care; however, it is still possible that pharmaceutical 
care improved despite the fact that we couldn’t measure it. 
Second, evidence based practice requires personalised deci-
sions, sometimes deviating from guidelines. Therefore, opti-
mal prescription outcomes for individual patients may not 
be optimally reflected in mean indicator scores: “the higher 
Table 1  Baseline characteristics of practices and patient populations
n number, IQR inter quartile range, SD standard deviation
a Using a five point scale of degree of urbanisation (in which 1 = highly urbanised area, 5 = rural area) [22]
b Data from Dutch Social and Cultural Planning Office, using status scores of zip code area of the general practice (in which a higher score repre-
sents a higher status) [23]
c Being a pharmacy located in the same building as where the general practice is located
d Using the UK Quality and Outcomes Framework and overview of chronic diseases developed by the Dutch National Institute for health and 
Environment [24, 25]
Intervention (n = 9 practices) Usual care (n = 10 practices) Usual care plus (n = 6 practices)
Practice characteristics
 Patients aged ≥ 18 years, median (IQR) 8669 (4765–10,689) 5973 (5371–6646) 6907 (4474 –13,981)
 Patients aged ≥ 50 years and using ≥ 1 medica-
tion chronically, median (IQR)
1899 (1262–2301) 1711 (1211–2369) 1768 (1480–3888)
 Degree of  urbanisationa, mean ± SD (range) 1.8 ± 1.1 (1–4) 2.1 ± 0.7 (1–3) 2.2 ± 0.8 (1–3)
 Socioeconomic  statusb, mean ± SD (range) 0.9 ± 1.0 (− 1.2–2.2) 0.6 ± 0.9 (− 2.1–1.7) 0.6 ± 0.5 (0–1.2)
 Healthcare centre, n (%) 7 (78) 7 (70) 3 (50)
 Indoor  pharmacyc, n (%) 6 (67) 6 (60) 4 (67)
Patient characteristics
 Patients aged ≥ 50 years and using ≥ 1 medica-
tion chronically, n
15,864 17,609 14,459
 Male sex, n (%) 7166 (45.2) 7966 (45.2) 6564 (45.4)
 Age in years, median (IQR) 63 (55–72) 63 (55–72) 63 (55–71)
 Number of chronic medications per patient, 
median (IQR)
3 (2–5) 3 (1–5) 3 (2–5)
 Number of  comorbiditiesd per patient, median 
(IQR)
2 (1–4) 2 (1–4) 3 (1–4)
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(or the lower) score the better” may not be the aim for every 
individual [30].
Last, limitations concerning the use of routine health-
care data need to be discussed. First, routine healthcare 
data are registered for healthcare use, not for research 
purposes. If data are not registered by GPs, they cannot 
be measured when using routine healthcare data [31]. 
Hence, they may reflect quality of registration more than 
quality of care provided. Second, as data of all patients 
registered in the practice are extracted, the problem of 
missing values arises as patients can ‘enter’ the data-
set when newly registering and ‘leave’ the dataset when 
deregistering. Overall, mixed models can handle missing 
data quite well, but this might still influence our findings. 
In line with this limitation is the problem of populations 
changing over time, which changes the case mix of prac-
tices. If characteristics of this case mix are related to the 
indicator, this might influence indicator findings. We tried 
to exclude such influence as much as possible during the 
assessment of indicators, however it might still be present 
to some extent [32]. Another problem of using data of all 
patients registered in the practice is that a final interven-
tion effect might be diluted: in the intervention group, we 
could not distinguish patients who had received an NDP-
led intervention from patients who had no NDP-led inter-
vention. Especially our choice to include a rather broad 
patient population (aged 50 years and older, using one 
or more chronic medications) might add to this potential 
dilution phenomenon. However, as we wanted to measure 
the complete intervention effect, we preferred this broader 
patient population over a more detailed population such 
as patients aged 65 years and older, with polypharmacy), 
even though the latter may reduce the dilution problem.
So, using extensive data sets such as routinely col-
lected healthcare data is not without limitations. We tried 
to counter these limitations by applying the same method 
Box 3  Topics of quality improvement projects, implemented by the NDPs (n)
a Topic is represented in the eventual selection of quality prescribing indicators
NDPs that imple-
mented the project 
(n)
Projects that intervened on specific quality prescribing
 Underprescribing of PPIs in patients using  NSAIDsa 6
 Underprescribing of inhalation corticosteroids in patients with asthma 5
 Underprescribing of statins in patients with a history of cardiovascular  diseasea 4
 Underprescribing of calcium and vitamin d in patients using bisphosphonates 4
 Underprescribing of vitamin D in patients aged over 70 years 4
 Therapeutic duplication of ACEi and AT-II  antagonista 6
 Contra-indicated NSAIDS in patients with a history of cardiovascular  diseasea 8
 Overuse of  benzodiazepinesa 4
 Overuse of bisphosphonates 4
 Overuse of paracetamol-codeine 1
 Overprescribing of  antidepressantsa 1
 Overprescribing of alpha-blockers in patients with LUTS 6
 Overprescribing of acetylsalicylic acid for primary cardiovascular risk prevention 5
 Overprescribing of inhalation corticosteroids in patients with COPD 1
 Overprescribing of triptans and starting preventive medication in patients with chronic migraine headache 5
 Overprescribing of PPIs 3
 Second-line antibiotics 1
 First-choice RAS-acting agents in new users 1
Projects that intervened on comprehensive quality prescribing
 Medication reconciliation after hospital discharge, taking all used medications into account 5
 Compliance with prescribing quality indicators measuring effective prescribing in primary care, defined by the Dutch 
Institute for Rational Use of Medicine (IVM)
2
Projects that intervened on organisation of care, underlying quality prescribing
 Optimise the organisation of referring to fellow GP with additional expertise in a specific (medication) field 1
 Optimise the exchange of information on medication prescriptions and medication lists between care providers 2
 Optimise registration of contra indications in the medical record 1
 Optimise the exchange of information on renal function between GP practice and community pharmacy 1
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in each study group and selecting indicators that are least 
susceptible to misinterpretation. However, we believe 
interpreting findings based on indicators measured in rou-
tine registry data remains uncertain. As a consequence, 
one should be aware of the above mentioned constraints 
that might put findings and comparisons at risk.
Implications for practice
This sub study, focused on measuring the impact of an 
NDP integrated in primary care with currently used quality 
indicators, showed no consistent effect of the intervention. 
Whether this indicates that the NDP does not adequately 
target the main prescribing problems in GP practice, or 
that the quality indicators used did not capture the NDP’s 
effectiveness around these problems remains unsolved. 
Taking results from the other sub studies of the POINT 
project into account [16, 29, 33], the latter option may 
be plausible as our intervention should be considered as 
complex [13, 34].
Table 2  Quality indicators of prescribing: percentages per study group and per study period and delta, uncorrected data
Indicators are represented as n numerator/n denominator (%) for the pre- and post-period, and for the % the difference between both periods is 
given. No correction for potential confounders was done
n number, Δ difference, PPI Proton Pump Inhibitor, NSAID Non Steroid Anti-Inflammatory Drug, LDL Low Density Lipoprotein, CVD Cardio-
vascular Disease, HCT Hydrochlorothiazide, ACEi Angiotensin-Converting Enzyme inhibitor, ATII-RA Angiotensin II type 2 receptor antagonist
a Pre-period: the year prior to the intervention year, namely 1 January 2013 until 31 December 2013; Post-period: the year in which the interven-
tion was conducted, namely 1 June 2014 until 31 May 2015
b This category contains indicators representing desirable care, hence on average applies: the higher the percentage, the better
c This category contains indicators representing undesirable care, hence on average applies: the lower the percentage, the better
Study group Intervention Usual care Usual care plus
Study  perioda Pre Post Δ Pre Post Δ Pre Post Δ
Underprescribingb
 1. PPIs and 
NSAIDs
634/769 (82.4) 596/710 (83.9) + 1.5 621/766 (81.1) 619/714 (86.7) + 5.6 619/690 (89.7) 551/595 (92.6) + 2.9















 3. HCT dose 127/499 (25.5) 95/453 (21.0) − 4.5 149/525 (28.4) 124/509 (24.4) − 4.0 114/372 (30.6) 89/316 (28.2) − 2.5
 4. Digoxin 
dose
58/175 (33.1) 48/182 (26.4) − 6.8 47/128 (36.7) 44/150 (29.3) − 7.4 81/212 (38.2) 57/219 (26.0) − 12.2
Therapeutic duplicationc
 5. ACEi and 
ATII-RA
89/5858 (1.5) 77/6336 (1.2) − 0.3 71/6664 (1.1) 72/7281 (1.0) − 0.1 131/6223 (2.1) 105/6396 (1.6) − 0.5
Contra-indicatedc





301/3378 (8.9) − 4.7 378/3398 
(11.1)













































− 0.2 608/925 (65.7) 661/979 (67.5) + 1.8
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Conclusion
We assessed the effect of NDPs integrated in primary care 
teams on the quality of prescribing by GPs, using a compiled 
set of indicators. Although scores on all prescribing quality 
indicators improved after introduction of the NDP, we could 
not demonstrate a consistent improvement in prescribing qual-
ity in comparison with usual pharmaceutical care. To evaluate 
such a complex intervention however, in addition to measuring 
effects on quality, the “how” and “why” of (absence) of effects 
needs to be addressed as well to fully understand these results.
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article are included in the article’s Creative Commons licence, unless 
indicated otherwise in a credit line to the material. If material is not 
included in the article’s Creative Commons licence and your intended 
use is not permitted by statutory regulation or exceeds the permitted 
use, you will need to obtain permission directly from the copyright 
holder. To view a copy of this licence, visit http://creat iveco mmons 
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Table 3  Quality indicators of 
prescribing in the intervention 
year: comparison between 
intervention and control 
groups, corrected for potential 
confounders (relative risks, 95% 
CI, p-value)
Differences on scores of indicators are represented as adjusted relative risks with corresponding 95% confi-
dence intervals and p-values. Numbers result from the mixed models, correcting for potential confounders 
(on patient level: age, sex, the number of medications used and the number of comorbidities; on practice 
level: socioeconomic status and degree of urbanisation) and if needed, correction for clustering on practice 
level using random intercepts
a Indicator represents desirable care, hence a corrected relative risk greater than 1 resembles a positive 
intervention effect compared to the control group (in italics if statistically significant), and a relative risk 
below 1 resembles a negative intervention effect compared to the control group (in bold if statistically sig-
nificant)
b Indicator represents undesirable care, hence a corrected relative risk lower than 1 resembles a positive 
intervention effect compared to the control group (in italics if statistically significant), and a relative risk 
greater than 1 resembles a negative intervention effect compared to the control group (in bold if statistically 
significant)
Intervention vs. usual care in post-
year
Intervention vs. usual care plus 
in post-year
Underprescribinga
 1. PPIs and NSAIDs 0.96 (0.92–1.00) 0.066 0.91 (0.87–0.94)  < 0.001
 2. LDL in CVD history 1.02 (0.96–1.09) 0.504 0.99 (0.92–1.05) 0.661
Dosing errorb
 3. HCT dose 0.85 (0.60–1.21) 0.373 0.71 (0.52–0.97) 0.030
 4. Digoxin dose 0.92 (0.65–1.31) 0.652 1.07 (0.67–1.70) 0.780
Therapeutic duplicationb
 5. ACEi and ATII-RA 1.24 (0.88–1.75) 0.223 0.94 (0.58–1.54) 0.808
Contra-indicatedb
 6. NSAIDs in CVD history 1.27 (1.01–1.61) 0.044 1.33 (1.05–1.69) 0.019
Medication not effectiveb
 7. Benzodiazepines 1.04 (0.78–1.39) 0.797 1.03 (0.77–1.38) 0.849
Overprescribingb
 8. Antidepressants 1.03 (0.83–1.28) 0.791 0.78 (0.59–1.03) 0.077
Inadequate monitoringa
 9. Diuretics monitoring 1.03 (1.01–1.05) 0.010 1.04 (1.01–1.06) 0.004
 10. Thyroid monitoring 1.00 (0.94–1.06) 0.873 0.99 (0.93–1.05) 0.697
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